Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

Dr Rachel Galot, medical oncologist at Cliniques Universitaires Saint-Luc in Brussels, presented the results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM), a phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

With the educational support of: